Jeepers, you would think that cancer immunotherapy has all of a sudden been banned by the FDA.
The after market action for DNDN is due to sale forecasts and not because of the science behind Provenge.
After market trading tends to be extremely volatile on the U.S. markets. It should bounce back somewhat tomorrow. If it doesn't you would think that DNDN would be a takeover target.
The DNDN sales team need to get out on the road an educate.
It's a pity Obama and his medicare/medicaid issues are creating all this confusion for DNDN.
Provenge has full coverage. DNDN just need to get the word out there!
top up opportunity - technical counsel. , page-7
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.005(1.59%) |
Mkt cap ! $465.4M | |||
| Open | High | Low | Value | Volume |
| 31.5¢ | 32.5¢ | 31.0¢ | $1.599M | 5.009M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 65758 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 6777 | 1 |
View Market Depth
| Last trade - 16.10pm 19/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |